Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 21, 2018
Pharmacy Choice - Pharmacy News - July 21, 2018

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
7/21/18 - FDA Approves First Targeted Treatment for Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Have a Certain Genetic Mutation
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. "Tibsovo is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH1 mutation," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the
7/20/18 - AGIOS PHARMACEUTICALS INC FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On July 20, 2018, Agios Pharmaceuticals, Inc. issued a press release announcing that TIBSOVO ® was granted approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA approved test.
7/20/18 - Astellas Pharma Inc. - U.S. FDA Approves XTANDI for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer
TOKYO and NEW YORK- Astellas Pharma Inc. and Pfizer Inc. today announced the U.S. Food and Drug Administration approved a supplemental New Drug Application for XTANDI, following FDA Priority Review designation, based on results from the Phase 3 PROSPER trial. The FDA action broadens the indication for XTANDI to men with castration-resistant prostat
7/20/18 - FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
--The U.S. Food and Drug Administration today approved Tibsovo tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who have a specific genetic mutation. "Tibsovo is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH1 mutation," said Richard Pazdur, M.D
7/20/18 - FDA grants approval for first breast cancer drug through `Real-Time Oncology Review` [Syrian Arab News Agency]
With this real-time review, the FDA was able to start evaluating the clinical data as soon as the trial results become available, enabling FDA to be ready to approve the new indication upon filing of a formal application with the Agency. The first new program, called Real-Time Oncology Review, allows for the FDA to review much of the data earlier,
7/20/18 - FDA Grants Approval of Agiosâ?? Pharmaceuticalsâ?? TIBSOVO®
Agios Pharmaceuticals has announced that TIBSOVO was granted approval from the US Food and Drug Administration for treatment of adult patients with relapsed or refractory acute myeloid leukemia. â??The FDA approval of TIBSOVO ®â?? our first wholly owned drug and the second approved medicine from our research platform in less than a yearâ?? is an i

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415